Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

F4/Asabys Partners/Activity

Asabys Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

iPremom raised a €15M seed round for early molecular prediction of pregnancy complications, led by Amadeus Capital Partners with Asabys participating.

iPrenom

iPrenom Asabys Partners

amadeuscapital.comSEP 2, 2026

asabys.com

Asabys Partners | Activity | F4

SEP 2, 2026

Exit

Oculis signed an asset purchase agreement for Accure Therapeutics' lead CNS asset.

Accure Therapeutics

Accure Therapeutics Asabys Partners

investors.oculis.comAUG 10, 2026

AUG 10, 2026

Team Change

Asabys-backed Oriva Therapeutics appointed Dr Agnès Arbat as CEO to advance its clinical-stage women's health pipeline.

Dr Agnès Arbat appointed CEO of Oriva Therapeutics

Oriva Asabys Partners

asabys.comJUN 11, 2026

JUN 11, 2026

Investment

Ona Therapeutics raised an oversubscribed $86.6M Series B, co-led by Columbus Venture Partners and Mérieux Equity Partners, with participation from existing investors including Asabys.

Ona Therapeutics

Ona Therapeutics Asabys Partners

asabys.comJUN 4, 2026

JUN 4, 2026

New Fund

Asabys launched a new fund of up to €120M focused on technology transfer and company creation in biotechnology and medtech, after selection into the CDTI/EIF Innvierte Deep Start initiative.

Asabys Innvierte Tech Transfer FCRE

Asabys Partners

asabys.comMAY 20, 2026

MAY 20, 2026

News

Spain's Ministry of Science via CDTI, together with the EIF, invested €74.7M in the Asabys Innvierte Tech Transfer fund to boost biotech and medtech company creation.

CDTI and EIF invest €74.7M in Asabys Innvierte Tech Transfer fund

Asabys Partners

asabys.comMAY 19, 2026

MAY 19, 2026

Team Change

Asabys portfolio company Medasense appointed MedTech veteran Peter Wehrly as Executive Chairman of the Board.

Peter Wehrly appointed Executive Chairman of Medasense

MedaSense Asabys Partners

asabys.comFEB 25, 2026

FEB 25, 2026

Milestone

Oriva Therapeutics launched publicly with Asabys backing to advance novel treatments in women's health.

Oriva

Oriva Asabys Partners

asabys.comFEB 3, 2026

FEB 3, 2026

Team Change

Asabys portfolio company Orikine Bio appointed Larry Edwards as Chairman of its Board of Directors.

Larry Edwards appointed Chairman of Orikine Bio

Orikine Bio Asabys Partners

asabys.comJAN 22, 2026

JAN 22, 2026

Investment

Qida raised Spain's largest eldercare funding round at €37M to expand in-home senior care services.

Qida

Qida Asabys Partners

eu-startups.comNOV 2025

NOV 2025

News

Asabys integrated Aliath Bioventures (formerly Alta Life Sciences) in partnership with AltamarCAM Partners, growing combined AUM to over $468M with a goal of exceeding €1B by 2030.

Asabys integrates Aliath Bioventures in $468M strategic consolidation

Asabys Partners

bioxconomy.comOCT 2025

OCT 2025

Milestone

SpliceBio secured a $135M Series B, backed by Sanofi and Roche, to advance its gene therapy pipeline for Stargardt disease.

SpliceBio

SpliceBio Asabys Partners

splice.bioJUN 11, 2025

JUN 11, 2025

Investment

Deepull closed an oversubscribed €50M Series C to advance its UllCORE sepsis diagnostic system.

deepull

deepull Asabys Partners

globenewswire.comAPR 29, 2025

APR 29, 2025

Investment

Anaconda Biomed secured a €20M funding round to advance its next-generation thrombectomy systems for ischemic stroke.

Anaconda

Anaconda Asabys Partners

asabys.comJAN 2025

JAN 2025

Page 1 of 2